{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T10:40:06Z","timestamp":1784025606441,"version":"3.55.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.jns.2011.05.035","type":"journal-article","created":{"date-parts":[[2011,6,24]],"date-time":"2011-06-24T00:19:27Z","timestamp":1308874767000},"page":"124-127","source":"Crossref","is-referenced-by-count":66,"title":["Thromboembolic complications of intravenous immunoglobulin therapy in patients with neuropathy: A two-year study"],"prefix":"10.1016","volume":"308","author":[{"given":"Yusuf A.","family":"Rajabally","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Kearney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2011.05.035_bb0005","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2174\/157015909790031166","article-title":"Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies","volume":"7","author":"Jacob","year":"2009","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.jns.2011.05.035_bb0010","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/00002826-199710000-00002","article-title":"Side effects of high-dose intravenous immunoglobulins","volume":"20","author":"Stangel","year":"1997","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.jns.2011.05.035_bb0015","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1001\/archneurol.2010.223","article-title":"IGIV-C CIDP Efficacy (ICE) Study Group Safety and tolerability of immune globulin intravenous in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"67","author":"Donofrio","year":"2010","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2011.05.035_bb0020","first-page":"222","article-title":"Intravenous immunoglobulins in neurological disorders: safety issues","volume":"S4","author":"Eibi","year":"2003","journal-title":"Neurol Sci"},{"key":"10.1016\/j.jns.2011.05.035_bb0025","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1007\/s00415-003-1085-1","article-title":"Side effects of intravenous immunoglobulins in neurological autoimmune disorders \u2014 a prospective study","volume":"250","author":"Stangel","year":"2003","journal-title":"J Neurol"},{"key":"10.1016\/j.jns.2011.05.035_bb0030","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000073059","article-title":"Therapy with intravenous immunoglobulins: complications and side-effects","volume":"50","author":"Wittstock","year":"2003","journal-title":"Eur Neurol"},{"key":"10.1016\/j.jns.2011.05.035_bb0035","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1212\/WNL.44.2.223","article-title":"High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events","volume":"44","author":"Dalakas","year":"1994","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2011.05.035_bb0040","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1111\/j.1365-2133.2006.07390.x","article-title":"Intravenous immunoglobulin-associated arterial and venous thrombosis; report of a series and review of the literature","volume":"155","author":"Marie","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jns.2011.05.035_bb0045","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1212\/01.WNL.0000068335.01620.9D","article-title":"The clinical features of 16 cases of stroke associated with administration of IVIg","volume":"60","author":"Caress","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2011.05.035_bb0050","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00415-009-0969-0","article-title":"Case\u2013control study of thromboembolic events associated with IV immunoglobulin","volume":"256","author":"Caress","year":"2009","journal-title":"J Neurol"},{"key":"10.1016\/j.jns.2011.05.035_bb0055","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1385\/CRIAI:29:3:173","article-title":"Intravenous immunoglobulin: adverse effects and safe administration","volume":"29","author":"Orbach","year":"2005","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jns.2011.05.035_bb0060","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/mus.20532","article-title":"Acute inflammatory demyelinating polyneuropathy: contribution of a dispersed compound muscle action potential to electrodiagnosis","volume":"33","author":"Cleland","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2011.05.035_bb0065","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/j.1468-1331.2009.02930.x","volume":"17","author":"Van den Bergh","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jns.2011.05.035_bb0070","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1111\/j.1468-1331.2006.01466.x","article-title":"European Federation of Neurological Societies\/Peripheral Nerve Society guideline on management of multifocal motor neuropathy","volume":"13","author":"European Federation of Neurological Societies","year":"2006","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jns.2011.05.035_bb0075","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/WNL.46.1.250","article-title":"Reversible encephalopathy with cerebral vasospasm in a Guillain\u2013Barr\u00e9 syndrome patient treated with intravenous immunoglobulin","volume":"46","author":"Voltz","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2011.05.035_bb0080","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/1096-8652(200009)65:1<30::AID-AJH5>3.0.CO;2-J","article-title":"Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations","volume":"65","author":"Wolberg","year":"2000","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jns.2011.05.035_bb0085","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1468-1331.2009.02802.x","article-title":"Italian Network for CIDP Register. A nationwide retrospective analysis on the effect of immune therapies in patients with chronic inflammatory demyelinating polyradiculoneuropathy","volume":"17","author":"Cocito","year":"2010","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jns.2011.05.035_bb0090","first-page":"1044","article-title":"Complications with plasma exchange","volume":"40","author":"Kimoto","year":"2000","journal-title":"Risho Shinkeigaku"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X11002978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X11002978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,2]],"date-time":"2018-12-02T02:51:59Z","timestamp":1543719119000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X11002978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":18,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0022510X11002978"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2011.05.035","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]}}}